Quarterly ResultApr 30, 2026, 07:02 AM
INDV Q1 Revenue +19% to $317M; Raises FY26 Guidance
AI Summary
Indivior Pharmaceuticals, Inc. reported strong first-quarter 2026 financial results, with total net revenue increasing 19% year-over-year to $317 million and SUBLOCADE net revenue growing 32% to $232 million. The company achieved a record quarterly Adjusted EBITDA of $164 million, up 112% year-over-year, and subsequently raised its full-year 2026 financial guidance for both net revenue and Adjusted EBITDA. Additionally, Indivior repurchased $125 million in shares, completed a $500 million convertible senior notes offering to repay existing debt, and announced the discontinuation of internal development for two pipeline assets, INDV-6001 and INDV-2000.
Key Highlights
- INDV Q1 Total Net Revenue $317M, up 19% YoY.
- INDV Q1 SUBLOCADE Net Revenue $232M, up 32% YoY.
- INDV Q1 Adjusted EBITDA $164M, up 112% YoY.
- Raised FY26 Net Revenue guidance to $1.215B-$1.285B.
- Raised FY26 Adjusted EBITDA guidance to $620M-$660M.
- Repurchased $125M in shares; $275M remains in program.
- Issued $500M convertible notes; repaid $333M term loan.
- Discontinued internal development of INDV-6001 and INDV-2000.
- Q1 GAAP Net Income $89M, up from $47M YoY.